Pharmacosmos A/S

Iron Deficiency Anemia Therapeutics Market Shows Promise with Emerging Therapies

6 months ago

• The iron deficiency anemia (IDA) therapeutics market is expected to grow, with a market size of around USD 1,400 million in the 7MM in 2023. • Emerging therapies like MPB-1514 (MegaPro Biomedical) and IDAX (Nemysis) show promise in improving treatment options for IDA patients. • Clinical trials are underway to evaluate the efficacy of novel oral iron formulations like IHAT for increasing serum ferritin levels. • Oral iron therapy remains the first-line treatment, but intravenous iron products like Monoferric (Pharmacosmos) offer alternatives.

Pharmacosmos Group Acquires G1 Therapeutics for $405 Million to Expand COSELA Access for Cancer Patients

9 months ago

• Pharmacosmos Group has successfully completed its acquisition of G1 Therapeutics for $7.15 per share, representing a 68% premium to G1's closing price before announcement and a total equity value of approximately $405 million. • The acquisition brings COSELA (trilaciclib), the first and only FDA-approved therapy for chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer patients, into Pharmacosmos' portfolio of hematology and supportive care products. • Pharmacosmos plans to leverage its global commercial presence and expertise in hematology to expand COSELA's availability beyond the US and China markets, with plans to pursue registration in the UK and EU.